The case of T-ALL presenting with NK phenotype after COVID-19 vaccination.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 29 10 2022
revised: 09 01 2023
accepted: 14 01 2023
pubmed: 28 1 2023
medline: 15 2 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

NK-lymphoblastic leukemia/lymphoma (NK-LL) is an extremely rare hematopoietic tumor consisting of natural killer (NK) precursor cells, and their lineage overlaps with T-cells, making it challenging to diagnose. COVID-19 vaccination is recommended for people with a risk of aggravation such as cancer-bearing patients, including hematopoietic tumors. We present a 55-year-old man who had cervical lymph node swelling post vaccination for COVID-19. Hematological malignancy was suspected due to the presence of atypical lymphoid cells with an elevated IL-2R in laboratory data. Tumor cells were positive for CD7, CD56, cyCD3, and terminal deoxynucleotidyl transferase (TdT) evidenced through flow cytometry of the bone marrow and the lymph node. The histopathological findings showed monotonous tumor cell proliferation, the cells being positive for CD3 and TdT in the bone marrow and they were positive for CD3, TdT, and CD56 in lymph node. Even though these findings suggested NK-LL, clonal T-cell receptor (TCR) β gene rearrangement by Southern blot hybridization was observed in the bone marrow. TCRβ rearrangement led to the final diagnosis of T-cell lymphoblastic leukemia (T-ALL). The causal relationship between COVID-19 vaccination and carcinogenesis is not clear, and more cases need to be studied in order to elucidate the relationship between the two factors.

Identifiants

pubmed: 36706586
pii: S0344-0338(23)00010-9
doi: 10.1016/j.prp.2023.154310
pmc: PMC9840814
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

154310

Informations de copyright

Copyright © 2023 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest Authors have no conflict of interest to declare.

Auteurs

Eriko Yanagida (E)

Department of Pathology, National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan; Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. Electronic address: eriko_yanagida@med.kurume-u.ac.jp.

Akira Kubota (A)

Department of Hematology, National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan.

Hiroaki Miyoshi (H)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Koichi Ohshima (K)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Toshiro Kawakita (T)

Department of Hematology, National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan.

Toshihiko Murayama (T)

Department of Pathology, National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH